A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Cutting-edge Wound Care Systems to Aid injured Ukrainians – Thanks to RedDress, a Florida-based Medical Company

RedDress, a Florida-based Israeli medical company is shipping revolutionary blood-clotting wound care systems to Ukraine to help with serious injuries and severe trauma wounds, RedDress announced in a press release Wednesday.

RedDress began shipments of 400 of their ActiGraft systems this week to multiple hospitals in Ukraine to help treat civilian casualties as a result of the indiscriminate Russian attacks.

[mks_pullquote align=”left” width=”300″ size=”24″ bg_color=”#1e73be” txt_color=”#ffffff”]“We’re grateful we’re in a position to not only have a cutting-edge product that has a far greater success rate than traditional wound care treatment options, but also that we have the ability to be financially capable to donate these resources to help so many people in need,”[/mks_pullquote]

In addition to donating the FDA-cleared wound care product, RedDress is coordinating with their partner medical specialists from GraftIn and SlavaMed to help with delivery into Ukraine, while another partner, Dr. Arkadiy Savchenko, a leading expert and Department Surgery No. 2 of Danylo Halytsky Lviv National Medical University, will lead the charge to teach Ukrainian nurses, doctors and aid workers, on how to use the systems.

“We’re grateful we’re in a position to not only have a cutting-edge product that has a far greater success rate than traditional wound care treatment options, but also that we have the ability to be financially capable to donate these resources to help so many people in need,” said Robert Mueller, general manager of RedDress.

According to RedDress, this is the first time their technology will be deployed and used in a war zone. However, their experts believe it will not be the last.

ActiGraft is a new, proprietary and patented technology solution used to help with wound care that enables health care providers to produce – in real time – in vitro blood clots from a patient’s whole blood. Once applied, the blood clot supports wound management and naturally occurring processes in the patient’s body.

While still considered new technology, ActiGraft is quickly becoming a preferred treatment option, especially by doctors who treat complex wounds like those often seen in amputations, post-surgical patients, diabetic patients, vascularly compromised patients, and patients suffering from chronic and traumatic wounds. Showcasing the broad use, just last year, RedDress’s ActiGraft was recognized as one of the year’s Top 10 Innovations by Podiatry Today, a medical trade journal.

The systems are expected to be delivered to Ukraine this week and could be used in the field as early as next week.

RedDress is a privately held, Israel-based company with a U.S. subsidiary, RedDress Ltd., located in Ponte Vedra Beach, Florida. Founded in 2009 with the goal of developing more effective, natural, and economically viable treatments for chronic wounds, RedDress is committed to improving the health and lives of patients around the world with its latest innovation – ActiGraft.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.
“We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, M.D., Chief Medical Officer of Enliven. “Across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population that includes post-asciminib patients, with a preliminary safety profile consistent with its highly selective design. Not only did all evaluable patients have improved or stable BCR::ABL1 transcript levels, but, importantly, 89% of all patients enrolled remain on study. We believe the initial data demonstrate the potential clinical utility of ELVN-001 for all types of patients, including those that are earlier in the treatment paradigm.”
The partnership is with Health-HavenRx ™, an online pharmacy platform. This partnership enables a new, convenient channel for patients to access POGO Automatic by using their health insurance on Intuity Medical’s e-commerce website at www.GoodtoPogo.com.

By using this website you agree to accept Medical Device News Magazine Privacy Policy